Lymphatic activation of ACKR3 signaling regulates lymphatic response after ischemic heart injury

Insights

Atypical chemokine receptor 3 (ACKR3) activation in cardiac lymphatics improves survival and reduces edema after ischemic heart injury. Blocking ACKR3 promotes a denser lymphatic network, aiding recovery from heart damage.

Area of Science:

  • Cardiovascular Biology
  • Lymphatic System Research
  • Molecular Cardiology

Background:

  • Ischemic heart disease is a leading global cause of mortality and morbidity.
  • Cardiac lymphatic expansion post-injury suggests a role in mitigating edema and inflammation.
  • Mechanisms linking hypoxia to cardiac lymphangiogenesis and function remain largely unknown.

Purpose of the Study:

  • To investigate the role of the adrenomedullin decoy receptor, atypical chemokine receptor 3 (ACKR3), in the cardiac lymphatic response to ischemic injury.
  • To elucidate the function of ACKR3 in cardiac lymphangiogenesis and edema resolution under hypoxic conditions.

Main Methods:

  • Utilized ACKR3-Tango-GFP reporter mice for spatial assessment of ACKR3 signaling post-ischemic heart injury.
  • Investigated the function of ACKR3 in Ackr3 knockout mice and cultured human lymphatic endothelial cells (LECs) under hypoxia.
  • Performed transcriptomic analysis to identify gene expression changes in cardiac lymphatics.

Main Results:

  • ACKR3 signaling was activated in cardiac lymphatics adjacent to ischemic injury sites (LAD ligation).
  • Ackr3 knockout mice showed improved survival, reduced acute edema, and a denser lymphatic network post-injury.
  • ACKR3 regulates cell-cell junction dynamics in LECs under hypoxia and influences cardiac lymphatic gene expression related to matrix remodeling and immune activation.

Conclusions:

  • Lymphatic ACKR3 expression is critical for lymphangiogenesis, edema protection, and survival following ischemic heart injury.
  • ACKR3 modulates adrenomedullin's cardioprotective effects in heart failure by regulating lymphatic functions.
  • These findings provide insights into the therapeutic potential of targeting ACKR3 in ischemic heart disease.
Abstract